IBM
IBM
$248.37
-0.29%
International Business Machines Corporation (IBM) is a global technology incumbent that operates across software, IT consulting, and hardware infrastructure, serving enterprise customers with products including Red Hat, watsonx, and mainframe systems that handle mission-critical workloads in finance, retail, and other regulated industries. With roughly 287,000 employees and operations in 175 countries, IBM is a legacy enterprise platform company whose competitive identity rests on hybrid-cloud software, AI-enabled consulting, and deep relationships with 95% of the Fortune 500 rather than on consumer or hyperscale cloud leadership. The current investor narrative is dominated by the tension between IBM's AI and quantum ambitions and a sharp deterioration in near-term fundamentals: a July 2026 profit warning and revenue miss triggered a roughly 25% single-day plunge, with headlines citing customers shifting budgets toward AI infrastructure and away from traditional consulting and services. Management is attempting to reposition the story around quantum computing (via the HRL Laboratories acquisition) and AI-driven software, but the market remains skeptical about whether these catalysts can offset cyclicality in consulting and infrastructure, leaving IBM a debated value-and-turnaround name rather than a momentum leader.…
IBM
IBM
$248.37
Related headlines
Investment Opinion: Should I buy IBM Today?
IBM warrants a Hold rating. The core thesis is that IBM offers deep value on forward earnings (forward PE 18.48x, PEG 0.35) and a defensive dividend (2.27% yield), but near-term fundamental deterioration and competitive pressures limit upside until AI and quantum initiatives show tangible results. The analyst consensus is 'buy' with an average target of $245.35, implying just 0.8% upside, suggesting the stock is fairly valued after its recent recovery.
Supporting evidence includes: 1) Forward PE of 18.48x on estimated EPS of $12.56, a 29% discount to trailing PE, indicating earnings growth expectations; 2) TTM free cash flow of $14.58 billion, which comfortably covers the dividend with a 59.05% payout ratio; 3) Gross margin of 58.19% and operating margin of 18.50%, demonstrating profitability despite compression; 4) Analyst high target of $350, offering 43.9% upside if AI and quantum catalysts materialize. However, the stock trades at a price-to-book of 8.46x, near the high end of its historical range, and revenue growth is lumpy with a July profit warning.
The biggest risks are: 1) Continued consulting revenue decline due to AI budget rotation; 2) Margin compression and earnings volatility; 3) High leverage (debt-to-equity 2.06) and liquidity concerns (current ratio 0.93). The rating would upgrade to Buy if forward PE compresses below 16x or if AI/quantum revenue shows double-digit growth, and downgrade to Sell if revenue growth turns negative or if the $199 support breaks. Relative to its history and peers, IBM appears fairly valued, with the market pricing in a modest recovery.
Sign up to view all
IBM 12-Month Price Forecast
IBM presents a balanced risk/reward profile. The deep value on forward earnings and strong free cash flow provide downside support, but the deteriorating consulting business and competitive pressures limit upside. The analyst consensus is mildly bullish with a $245 target, but the negligible upside suggests the stock is fairly valued. A breakthrough in AI or quantum could drive the bull case, while a continued revenue decline could trigger the bear case. I would upgrade to bullish if AI revenue shows double-digit growth and consulting stabilizes, and downgrade to bearish if revenue growth turns negative or margins fall below 15%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IBM's 12-month outlook, with a consensus price target around $245.35 and implied upside of -1.2% versus the current price.
Average Target
$245.35
0 analysts
Implied Upside
-1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$174 - $350
Analyst target range
IBM is covered by 23 analysts with a consensus recommendation of "buy" (recommendation mean of 2.2 on a scale where 1 is strong buy and 5 is strong sell), and the average target price of $245.35 implies just +0.8% upside from the current $243.29, indicating the consensus sees the stock as essentially fairly valued after its recovery. The Buy/Hold/Sell distribution skews constructive but not euphoric, with recent actions showing a mix: JP Morgan upgraded to Overweight from Neutral on June 23, 2026, while HSBC downgraded to Reduce from Hold on July 14, 2026, and Morgan Stanley maintained Equal Weight, reflecting genuine disagreement about the AI transition's impact on IBM's consulting business. The consensus leans mildly bullish but the negligible implied upside suggests analysts believe the easy money has been made and the stock needs fundamental proof before targets move higher. The target range is exceptionally wide, from a low of $174.00 to a high of $350.00, a spread of $176 or roughly 72% of the current price, which signals very high uncertainty about IBM's trajectory. The high target of $350 assumes successful execution on quantum computing and AI software monetization, multiple expansion back toward historical highs, and a resolution of the consulting headwind, while the low target of $174 prices in continued margin compression, further customer budget rotation away from traditional services, and a retest of the 52-week low. The wide dispersion, combined with the recent downgrade-to-upgrade churn, indicates analysts lack conviction on the AI narrative's timing, and the estimated revenue range of $80.08 billion to $83.09 billion (average $81.47 billion) against estimated EPS of $12.28 to $12.88 (average $12.56) shows the fundamental estimates themselves are tightly clustered even as price targets diverge wildly, suggesting the disagreement is about multiple and sentiment rather than near-term earnings.
Drowning in data?
Find the real signal!
Bulls vs Bears: IBM Investment Factors
The bear case currently has stronger evidence due to the July profit warning, revenue miss, and 25% plunge, which exposed structural challenges in IBM's consulting business as customers pivot to AI infrastructure. However, the bull case rests on deep value (forward PE 18.48x, PEG 0.35), strong free cash flow ($14.58B), and a defensive beta (0.708) that could attract income and value investors. The single most important tension is whether IBM's AI and quantum investments can offset the cyclical decline in traditional services; if they can, the stock could re-rate toward $350, but if not, it risks retesting the $199 low. Analyst consensus is mildly bullish with a $245.35 average target, but the negligible upside suggests the market needs fundamental proof before committing. The wide target dispersion ($174-$350) underscores the high uncertainty and the need for a catalyst to resolve the debate.
Bullish
- Deep Value on Forward Earnings: IBM trades at a forward PE of 18.48x on estimated EPS of $12.56, a 29% discount to its trailing PE of 26.07x. The PEG ratio of 0.35 is strikingly low, suggesting the stock is cheap relative to expected growth if analyst estimates hold.
- Strong Free Cash Flow and Dividend: TTM free cash flow is $14.58 billion, comfortably covering the 2.27% dividend yield with a 59.05% payout ratio. This provides a margin of safety and supports continued shareholder returns even amid earnings volatility.
- Analyst Consensus Buy with Upside: 23 analysts rate IBM a 'buy' with a mean recommendation of 2.2 and an average target price of $245.35, implying 0.8% upside from $243.29. The high target of $350 suggests significant optionality if AI and quantum initiatives gain traction.
- Defensive Low-Beta Profile: With a beta of 0.708, IBM is roughly 29% less volatile than the market, offering downside protection in turbulent times. Its 32.45% ROE and 58.19% gross margin demonstrate underlying profitability and pricing power.
Bearish
- Severe Revenue and Profit Warning: The July 2026 profit warning and revenue miss triggered a 25% single-day plunge, with customers shifting budgets toward AI infrastructure and away from traditional consulting. Q2 2026 revenue was incomplete but prior-year Q2 2025 was $16.98 billion, and the forward trajectory is deteriorating.
- Margin Compression and Earnings Volatility: Q1 2026 net margin was 7.64%, down from 7.26% in Q1 2025, and well below Q4 2025's 28.45%. The extreme seasonality with Q4 carrying the profit load makes quarterly results unpredictable and vulnerable to misses.
- High Leverage and Liquidity Concerns: Debt-to-equity is 2.06 and the current ratio is 0.93, below 1.0, indicating potential short-term liquidity tightness. The Q2 2026 cash flow statement shows a $10.46 billion acquisition outflow funded partly by a $10.72 billion net cash increase, leaning on the balance sheet.
- Relative Underperformance and Downtrend: IBM is down 5.34% over the past year and 16.54% YTD, versus the S&P 500's +16.22% and +12.08% gains, producing a relative strength of -21.56% over 12 months. The 37.5% maximum drawdown confirms a violent de-rating event.
IBM Technical Analysis
IBM is in a damaged but stabilizing trend: the stock is down 5.34% over the past year and 16.54% year-to-date, a stark underperformance versus the S&P 500's +16.22% 1-year and +12.08% YTD gains, producing a relative strength of -21.56% over 12 months. At the current price of $243.29, IBM sits at roughly 73% of its 52-week range (low $199.19, high $332.46), meaning it has recovered materially off the July lows but remains well below the highs, consistent with a post-capitulation recovery rather than a sustained uptrend. The 37.5% maximum drawdown confirms this was a violent de-rating event, and positioning here implies the stock is neither an oversold falling knife nor a breakout leader, but a range-bound recovery candidate. Recent momentum is improving but fragile: the stock is up 3.10% over the past month and 3.96% on the latest session, yet still down 10.63% over three months and 1.21% over six months, showing that short-term strength is a rebound within a medium-term downtrend. The 1-month relative strength of +4.16% versus SPY indicates IBM is finally outperforming the index over the near term, a potential early sign of mean reversion after extreme weakness, though the 3-month relative strength of -13.67% shows the damage is far from repaired. Key levels are clear: the $199.19 52-week low is the critical support that must hold to validate the recovery thesis, while the $332.46 high represents major resistance that would require a fundamental catalyst to reclaim. With a beta of just 0.708, IBM is roughly 29% less volatile than the market, which supports defensive position sizing but also means it lacks the torque to rapidly recover lost ground; a breakdown below $199 would signal renewed institutional selling, while a sustained move above $260-$270 would confirm the bottoming pattern.
Beta
0.71
0.71x market volatility
Max Drawdown
-37.5%
Largest decline past year
52-Week Range
$199-$332
Price range past year
Annual Return
-3.1%
Cumulative gain past year
| Period | IBM Return | S&P 500 |
|---|---|---|
| 1m | +6.0% | -2.4% |
| 3m | -5.3% | +2.2% |
| 6m | -0.8% | +14.8% |
| 1y | -3.1% | +14.6% |
| ytd | -14.8% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBM Fundamental Analysis
IBM's revenue trajectory is lumpy and decelerating at the headline level: Q1 2026 revenue was $15.92 billion with net income of $1.22 billion and EPS of $1.30, while the Q2 2026 filing shows gross profit of $9.91 billion but incomplete revenue and net income fields, and the prior-year Q2 2025 posted $16.98 billion in revenue with $2.19 billion net income. The year-over-year comparison is troubling: Q1 2026 revenue of $15.92 billion versus Q1 2025's $14.54 billion shows growth, but the July profit warning and revenue miss suggest the forward trajectory is deteriorating as customers redirect spend toward AI infrastructure. Segment data shows Software at $7.05 billion and Consulting at $5.27 billion as the largest contributors, with Infrastructure Services at $3.33 billion, meaning the consulting-heavy mix is precisely the area most exposed to the AI-driven budget rotation that triggered the selloff. Profitability remains solid but is compressing: gross margin stands at 58.19%, operating margin at 18.50%, and net margin at 15.68%, with Q1 2026 net income of $1.22 billion representing a 7.64% net margin that is well below Q4 2025's 28.45% net margin on $19.69 billion revenue and $5.60 billion net income. The quarterly net income pattern ($1.06B in Q1 2025, $2.19B in Q2 2025, $1.74B in Q3 2025, $5.60B in Q4 2025, $1.22B in Q1 2026) shows extreme seasonality with Q4 carrying the profit load, and the Q1 2026 margin compression versus Q1 2025's 7.26% net margin is marginal but directionally concerning given the profit warning. The balance sheet carries meaningful leverage: debt-to-equity is 2.06, the current ratio is 0.93 (below 1.0, indicating potential short-term liquidity tightness), and ROE is a strong 32.45% while ROA is a modest 5.30%. Free cash flow TTM is $14.58 billion, which comfortably covers the 2.27% dividend yield and 59.05% payout ratio, but the Q2 2026 cash flow statement shows operating cash flow of only $2.60 billion against $1.58 billion in dividends paid and a $10.46 billion acquisition outflow, funded partly by a $10.72 billion net cash increase, suggesting the company is leaning on its balance sheet for strategic M&A rather than organic cash generation.
Quarterly Revenue
$0.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$14.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBM Overvalued?
Because IBM is profitable (positive net income and EPS), the PE ratio is the primary metric: the trailing PE is 26.07x while the forward PE is 18.48x, a 29% compression that implies the market expects meaningful earnings growth ahead, consistent with analyst estimated EPS of $12.56 versus the current trailing EPS of roughly $0.04 (which appears distorted by the incomplete Q2 2026 filing). The forward PE of 18.48x on estimated EPS of $12.56 against a $243.29 price suggests the market is pricing in a recovery, but the gap between trailing and forward multiples also reflects the depressed trailing earnings base rather than pure optimism. On a price-to-sales basis, IBM trades at 4.09x with an EV/Sales of 4.02x and EV/EBITDA of 19.07x, while the PEG ratio of 0.35 is strikingly low, suggesting the stock is cheap relative to expected growth if those growth estimates hold. Peer comparison is difficult without explicit industry averages in the provided data, but IBM's 4.09x PS and 19.07x EV/EBITDA are moderate for a technology services firm with 58.19% gross margins and 18.50% operating margins, and the 8.46x price-to-book is rich relative to the 32.45% ROE, implying the market pays up for IBM's capital-light software mix. Historically, IBM's PE has ranged from roughly 11.4x (Q4 2023) to 54.5x (Q1 2025), with recent quarters at 46.6x (Q1 2026) and 12.4x (Q4 2025), so the current 26.07x trailing PE sits in the middle of its own band rather than at an extreme. The PS ratio of 4.09x is actually below the 14-16x range seen in 2025 quarterly data (though those figures appear to use different share counts), and the PB of 8.46x is near the high end of its historical 5.4x-10.0x range, suggesting the market is pricing in optimistic expectations about asset-light growth that may be hard to deliver given the consulting headwinds.
PE
26.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.1x
Enterprise Value Multiple
Investment Risk Disclosure
IBM faces significant financial and operational risks. The debt-to-equity ratio of 2.06 and current ratio of 0.93 indicate high leverage and potential short-term liquidity tightness, which could constrain flexibility if earnings deteriorate further. The Q2 2026 cash flow statement shows operating cash flow of only $2.60 billion against $1.58 billion in dividends and a $10.46 billion acquisition outflow, funded partly by a $10.72 billion net cash increase, suggesting reliance on balance sheet capacity for strategic M&A rather than organic cash generation. Additionally, revenue is concentrated in consulting ($5.27 billion) and software ($7.05 billion), with consulting particularly vulnerable to the AI-driven budget rotation that triggered the July profit warning. The extreme seasonality of earnings, with Q4 2025 net income of $5.60 billion versus Q1 2026's $1.22 billion, creates earnings volatility and makes quarterly results unpredictable.
Market and competitive risks are pronounced. IBM trades at a trailing PE of 26.07x and a price-to-book of 8.46x, which is near the high end of its historical 5.4x-10.0x range, leaving little room for multiple expansion if growth disappoints. The stock's beta of 0.708 offers some downside protection, but its relative strength of -21.56% over 12 months highlights severe underperformance versus the S&P 500. Competitive pressures are intensifying from AI-native firms like Arista Networks and Figma, which are capturing growth and investor attention, as noted in recent news. Regulatory headwinds are not prominent, but the shift in AI capital spending from GPU and cloud players to memory and storage companies, as highlighted in a July 2026 article, could further erode IBM's traditional revenue streams.
The worst-case scenario involves a continued decline in consulting revenue, margin compression, and a failure to monetize AI and quantum investments. If customers accelerate the shift away from traditional services and IBM's AI offerings fail to gain traction, the stock could retest its 52-week low of $199.19, representing a 18.1% decline from the current price of $243.29. The analyst low target of $174 implies a 28.5% downside, and the historical max drawdown of 37.5% shows the potential severity of a de-rating event. In this adverse scenario, an investor could lose 18% to 28% from current levels, with the possibility of further downside if the $199 support breaks.
FAQ
The key risks are: 1) Financial: high debt-to-equity of 2.06 and current ratio of 0.93, indicating liquidity tightness; 2) Operational: revenue concentration in consulting ($5.27B) and software ($7.05B), with consulting vulnerable to AI budget shifts; 3) Market: relative underperformance with -21.56% 1-year relative strength and a 37.5% max drawdown; 4) Competitive: AI-native firms like Arista and Figma are capturing growth. The most severe risk is a continued decline in consulting revenue, which could trigger a retest of the $199 low.
Our 12-month forecast has a base case (55% probability) of $230-$260, assuming modest revenue growth and stable margins. The bull case (25%) targets $300-$350 if AI and quantum initiatives gain traction, while the bear case (20%) targets $174-$199 if consulting declines accelerate. The most likely scenario is the base case, with the key assumption that IBM maintains its gross margin above 58% and free cash flow above $14 billion. Analyst average target of $245.35 aligns with our base case.
IBM appears fairly valued. Its forward PE of 18.48x is moderate for a technology services firm, and the PEG ratio of 0.35 suggests undervaluation relative to growth. However, the price-to-book of 8.46x is near the high end of its historical 5.4x-10.0x range, and the PS ratio of 4.09x is not cheap. The market is pricing in a recovery, as evidenced by the 29% compression between trailing and forward PE. Compared to peers, IBM's valuation is reasonable but not a bargain, implying the market expects earnings growth to materialize.
IBM is a nuanced buy. The stock trades at a forward PE of 18.48x, a 29% discount to its trailing PE, and offers a 2.27% dividend yield with strong free cash flow of $14.58 billion. Analyst consensus is 'buy' with an average target of $245.35, implying just 0.8% upside, suggesting the stock is fairly valued. The biggest downside risk is a retest of the 52-week low of $199.19, representing 18% downside, if consulting revenue continues to decline. For value and income investors with a long-term horizon, IBM can be a good buy on dips, but growth investors may find better opportunities elsewhere.
IBM is better suited for long-term investment. Its beta of 0.708 indicates lower volatility, and the 2.27% dividend yield with a 59.05% payout ratio appeals to income investors. However, the stock has high earnings seasonality and recent fundamental deterioration, making short-term trading risky. A minimum holding period of 2-3 years is recommended to allow AI and quantum investments to potentially pay off. Short-term traders might exploit range-bound moves between $199 and $260, but the risk/reward favors patient accumulation on weakness.
